Cargando…

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52‐week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque‐type psoriasis. Patients randomly received guselkumab 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuki, Mamitaro, Kubo, Hiroshi, Morishima, Hitomi, Goto, Ryosuke, Zheng, Richuan, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175099/
https://www.ncbi.nlm.nih.gov/pubmed/29905383
http://dx.doi.org/10.1111/1346-8138.14504